Results 131 to 140 of about 3,884 (159)

Immunological and physical evaluation of the multistage tuberculosis subunit vaccine candidate H56/CAF01 formulated as a spray-dried powder

Vaccine, 2018
Liquid vaccine dosage forms have limited stability and require refrigeration during their manufacture, distribution and storage. In contrast, solid vaccine dosage forms, produced by for example spray drying, offer improved storage stability and reduced dependence on cold-chain facilities.
Peter Andersen, Aneesh Thakur, Dennis Christensen   +2 more
exaly   +4 more sources

A stochastic modeling study of H56 block in Daqingzijing oilfield

Arabian Journal of Geosciences, 2015
After years of water injection, the underground movement of oil and water in Daqingzijing oilfield is becoming more and more complex, and the distribution of reservoir parameters between wells and remaining oil is difficult to predict. The reservoir geological model of H56 block in Daqingzijing oilfield is established with the support of numerous data ...
Jianpeng Hou, Fang Ding, Weilu Li
openaire   +1 more source

The multistage vaccine H56 boosts the effects of BCG to protect cynomolgus macaques against active tuberculosis and reactivation of latent Mycobacterium tuberculosis infection [PDF]

Journal of Clinical Investigation, 2012
It is estimated that one-third of the world's population is infected with Mycobacterium tuberculosis. Infection typically remains latent, but it can reactivate to cause clinical disease. The only vaccine, Mycobacterium bovis bacillus Calmette-Guérin (BCG), is largely ineffective, and ways to enhance its efficacy are being developed.
Philana Lin, Joanne Flynn, Jes Dietrich   +2 more
exaly   +3 more sources

Antiarrhythmic Properties of Stereoisomers of a Beta-adrenergic Blocking Agent (H56/28)

Anesthesiology, 1968
Cardiac arrhythmias were produced in the cat by inhalation of 1 per cent halopropane, 10 per cent CO2 and 89 per cent O2 and also by injection of epinephrine during inhalation of 1 per cent halopropane and 99 per cent O2. Dextro-H56/28, which has local anesthetic properties but only 1/40th the beta receptor blocking activity of the levo form of H56/28,
C O, Lord, R L, Katz, K E, Eakins
openaire   +2 more sources

H56 Driving performance of huntington’s disease gene carriers

Clinical care and clinical services, 2018
Background In patients with Huntington’s disease (HD), instrumental daily activities such as working and driving become affected at a relatively young age. For most patients, the decision to quit driving is difficult and affects their independence and social activities.
Milou Jacobs, Ellen P Hart, Yuri Mejia Miranda, Geert Jan Groeneveld, Joop MA van Gerven, Raymund AC Roos   +5 more
openaire   +1 more source

Immunogenicity of TB vaccine H56 in non-human primates (VAC4P.1113)

The Journal of Immunology, 2015
Abstract Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), remains a major global health problem. Several TB vaccine candidates are currently in various stages of development and clinical testing, including the protein subunit vaccine H56, from Statens Serum Institute (Copenhagen, Denmark).
Eileen Wong, Else Agger, Peter Andersen, JoAnne Flynn   +3 more
openaire   +1 more source

H1- and H56- subunit vaccines against TB - an overview of the clinical development

European Respiratory Journal, 2014
Despite a very effective worldwide vaccination program, BCG vaccination has proven to be insufficient to provide protection against TB disease, and a better vaccine is urgently needed. Statens Serum Institut has developed two TB vaccine candidates, H1:IC and its improved successor H56:IC.
Morten Ruhwald, Else Marie Agger, Søren T. Hoff, Peter L. Andersen   +3 more
openaire   +1 more source

First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults

Vaccine, 2015
H56:IC31 is a candidate tuberculosis vaccine comprising a fusion protein of Ag85B, ESAT-6 and Rv2660c, formulated in IC31 adjuvant. This first-in-human, open label phase I trial assessed the safety and immunogenicity of H56:IC31 in healthy adults without or with Mycobacterium tuberculosis (M.tb) infection.Low dose (15 μg H56 protein in 500 nmol IC31 ...
Peter Bang, Hassan Mahomed, Angelique Kany Kany Luabeya   +2 more
exaly   +3 more sources

H56 Comparison of the efficacy and safety of candesartan cilexetil 4, 8 and 12 mg with placebo and enalapril 10 mg in patients with mild to moderate essential hypertension [PDF]

American Journal of Hypertension, 1997
exaly   +2 more sources

Comparison ofβ-Adrenergic blocking activity of DCI, H56/28, ICI50172, LB46, methoxamine, MJ 1999 and propranolol in the blood perfused canine papillary muscle preparation

Experientia, 1970
Nachweis, dass derβ-Blocker LB46 am blutperfundierten Papillarmuskel des Hundes eine grossere Aktivitat aufweist als 6 andere bekannteβ-Blocker.
K, Hashimoto, M, Endoh, K, Tamura, N, Taira   +3 more
openaire   +2 more sources